Intervention

paliperidone

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7
Recruiting1
Common conditions7
Lead sponsors shown7
Advertisement

Clinical trials

7 shown
"Extended" (Alternate Day) Antipsychotic DosingNCT04478838 · 2022-06-06
RECRUITING
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · 2018-07-13
COMPLETED
Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia PatientsNCT01399450 · 2011-08-01
COMPLETED
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric HospitalNCT01193166 · 2010-08-01
WITHDRAWN
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic RegulationNCT01134731 · 2010-05-01
COMPLETED
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedNCT01157351 · 2010-05-01
COMPLETED
An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With SchizophreniaNCT00257023 · 2005-02-01
COMPLETED

Trial status mix

COMPLETED5
RECRUITING1
WITHDRAWN1

Phase mix

PHASE45
PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.